Liver and Bile

Gastroenterology. 2023;165(3):717–32

Intagliata NM, Rahimi RS, Higuera-de-la-Tijera F, Simonetto DA, Queiroz Farias A, Mazo DF, Boike JR, Stine JG, Serper M, Pereira G, Mattos AZ, Marciano S, Davis JPE, Benitez C, Chadha R, Méndez-Sánchez N, deLemos AS, Mohanty A, Dirchwolf M, Fortune BE, Northup PG, Patrie JT, Caldwell SH

Procedural-related bleeding in hospitalized patients with liver disease (PROC-BLeeD): An international, prospective, multicenter observational study


Background and aims: Hospitalized patients with cirrhosis frequently undergo multiple procedures. The risk of procedural-related bleeding remains unclear, and management is not standardized. The authors conducted an international, prospective, multicenter study of hospitalized patients with cirrhosis undergoing non-surgical procedures to establish the incidence of procedural-related bleeding and to identify bleeding risk factors.
Methods: Hospitalized patients were prospectively enrolled and monitored until surgery, transplantation, death, or 28 days from admission. The study enrolled 1187 patients undergoing 3006 non-surgical procedures from 20 centers.
Results: A total of 93 procedural-related bleeding events were identified. Bleeding was reported in 6.9% of patient admissions and in 3.0% of the procedures. Major bleeding was reported in 2.3% of patient admissions and in 0.9% of the procedures. Patients with bleeding were more likely to have non-alcoholic steatohepatitis (43.9% vs. 30%) and higher body mass index (BMI; 31.2 vs. 29.5). Patients with bleeding had a higher Model for End-stage Liver Disease (MELD) score at admission (24.5 vs. 18.5). A multivariable analysis controlling for center variation found that high-risk procedures (odds ratio [OR] = 4.64; 95% confidence interval [CI]: 2.44–8.84), MELD score (OR = 2.37; 95% CI: 1.46–3.86), and higher BMI (OR = 1.40; 95% CI: 1.10–1.80) independently predicted bleeding. Preprocedure international normalized ratio, platelet level, and antithrombotic use were not predictive of bleeding. Bleeding prophylaxis was used more routinely in patients with bleeding (19.4% vs. 7.4%). Patients with bleeding had a significantly higher 28-day risk of death (hazard ratio = 6.91; 95% CI: 4.22–11.31).

Conclusions: Procedural-related bleeding occurs rarely in hospitalized patients with cirrhosis. Patients with elevated body mass index and decompensated liver disease who undergo high-risk procedures may be at risk to bleed. Bleeding is not associated with conventional hemostasis tests, preprocedure prophylaxis, or recent antithrombotic therapy.

N. Intagliata, M.D., Associate Professor of Medicine, Division of Gastroenterology and Hepatology, University of Virginia Medical Center, Charlottesville, VA, USA, E-Mail: nmi4d@uvahealth.org

DOI: 10.1053/j.gastro.2023.05.046

Back to overview

this could be of interest:

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomized, double-blind, placebo-controlled, phase 3 trial

Lancet. 2023;401(10391):1853–65

A phase 3, randomized trial of bulevirtide in chronic hepatitis D

N Engl J Med. 2023;389(1):22–32

More articles on the topic